Background Patients with cancer have a substantial risk of recurrent thrombosis despite the
use of oral anticoagulant therapy. We compared the efficacy of a low-molecular-weight …

Background Several diagnostic strategies using ultrasound imaging, measurement of D-dimer,
and assessment of clinical probability of disease have proved safe in patients with …

Background Low-molecular-weight heparin is the standard treatment for cancer-associated
venous thromboembolism. The role of treatment with direct oral anticoagulant agents is …

Background Patients with acute proximal deep-vein thrombosis are usually treated first in
the hospital with intravenous standard (unfractionated) heparin. However, the longer plasma …

Background Patients who have a first episode of venous thromboembolism in the absence
of known risk factors for thrombosis (idiopathic thrombosis) are often treated with …

Background: The limitations of the current diagnostic standard, ventilation-perfusion lung
scanning, complicate the management of patients with suspected pulmonary embolism. We …

Background High-quality anticoagulation management is required to keep these narrow
therapeutic index medications as effective and safe as possible. This article focuses on the …

Background Many patients with the antiphospholipid antibody syndrome and recurrent
thrombosis receive doses of warfarin adjusted to achieve an international normalized ratio (INR) …

Background Skeletal complications are a major clinical manifestation of multiple myeloma.
These complications are caused by soluble factors that stimulate osteoclasts to resorb bone. …

Background Warfarin is very effective in preventing recurrent venous thromboembolism but
is also associated with a substantial risk of bleeding. After three months of conventional …